Frederick Munschauer, MD

At the 2016 CMSC Annual Meeting, Dr. Munschauer discussed the results of three studies that used real-world data to look at relapse rates, outpatients resource use, and costs related to patients taking subcutaneous interferon beta-1a as compared with other MS therapies.



Limelight Video

Next Article: